Risk-sharing in the Pharmaceutical Industry The Case of Out-licensing /
The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals...
Сохранить в:
| Главный автор: | |
|---|---|
| Соавтор: | |
| Формат: | Электронный ресурс eКнига |
| Язык: | English |
| Опубликовано: |
Heidelberg :
Physica-Verlag HD : Imprint: Physica,
2006.
|
| Редактирование: | 1st ed. 2006. |
| Серии: | Contributions to Management Science,
|
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1007/3-7908-1668-X |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Оглавление:
- Key Issues in Managing Pharmaceutical Innovation
- Risk-sharing as New Paradigm in Pharma R&D Collaborations
- Case Studies on Risk-sharing in Pharma R&D Collaborations
- Characteristics of Risk-sharing in Pharma R&D Collaborations
- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations
- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations
- Conclusion.